Boston Tech
Moderna’s Cancer Vaccine Finally Got Its Big Phase 3 Moment. The Footnotes Are Still in Cambridge.
Moderna and Merck say their personalized mRNA cancer vaccine met Phase 3 melanoma endpoints. The Cambridge biotech has a real win, with caveats.